UNH: Short Book Settles, Street Eyes the Gap to Consensus

UnitedHealth Group is in a holding pattern this week, with short interest frozen at 14.0 million shares for the second consecutive week and the stock trading at a widening discount to where analysts think it should be.

The positioning picture is unusually clean for a stock of this size. Short interest has not moved a share since the large cover that dropped the book from 15.95 million to 14.0 million in late October. At 1.55% of the free float, the position is low by any measure and sits near a six-month trough. Borrow availability is essentially unlimited, with over 893 million shares available relative to the short book, and cost to borrow has drifted back to 0.34%, well below the 0.49% level it touched in mid-October. Options are barely more animated: the put/call ratio is at 0.82, just half a standard deviation above its 20-day average of 0.82, and nowhere near the 0.94 high set over the past year. Nothing in the lending market or the options book signals any near-term conviction from the bear side.

The more interesting tension is on the Street. The analyst consensus is firmly bullish, but the stock at $404.44 trades at a 15% discount to the mean price target of $476.64. The most recent moves tell a split story: Wells Fargo trimmed its target from $526 to $487 on October 27 while keeping its Overweight rating, citing caution on the medical cost outlook. Morgan Stanley moved in the opposite direction the same day, nudging its target up to $531 from $529. Mizuho and RBC Capital both raised targets in the week prior, while Barclays and Baird cut theirs modestly after the Q3 print. The net result is a bullish consensus with a wide target dispersion, reflecting genuine disagreement about where medical costs land in 2027 rather than a directional call on the business. The PE multiple is running at 17.7x, up roughly half a turn over the past month, while EV/EBITDA has edged down slightly to 12.9x. Factor positioning reinforces the constructive lean: EPS momentum ranks in the 85th percentile on a 30-day basis, and the dividend score sits in the 98th percentile, though the analyst recommendation differential ranks near the bottom of the universe at the 4th percentile, reflecting how uniform the bullish clustering has become.

The bull and bear cases both hinge on medical costs. Bulls point to the Q3 print, where adjusted EPS came in at $4.69 against a $4.14 consensus, the medical loss ratio beat at 88.4%, and management lifted full-year 2026 adjusted EPS guidance to at least $20.50, implying growth above 25%. Bears argue that Medicare Advantage utilization is accelerating, that RAF score exposure under the v28 risk model creates a structural earnings drag, and that commercial cost pressures from specialty drugs and coding intensity are not yet fully reflected in guidance. The gap between the $487 Wells Fargo target and the $531 Morgan Stanley target captures that disagreement precisely: same rating, same general view on the franchise, different assumptions about where the medical cost line goes from here.

One piece of institutional movement worth noting: FMR (Fidelity) added 14.5 million shares in the quarter ending September 30, the largest absolute change among the top holders. BlackRock added 3.4 million shares over the same period. Neither move alters the ownership picture structurally, given the passive component of both, but the scale of Fidelity's addition is worth registering. The 13D/G register shows no activist presence; The Vanguard Group's 13G/A from March disclosed a drop to zero from a prior 10.08% stake, with Vanguard Capital Management separately filing a fresh 13G at 7.5% in April, reflecting a reorganisation of Vanguard's filing entities rather than an exit.

The next earnings event is scheduled for January 12, 2027, 69 days away. With short interest flat, borrow essentially free, and the options market relaxed, the question heading into year-end is whether the stock can close the gap to the Street consensus or whether the medical cost uncertainty keeps that discount in place.